SUMMARY Clinical preparations ofhorse antilymphocyte globulin(ALG) werefoundto inhibithuman bone marrow granulocyte colony growth. This effect was enhanced by complement and was dose dependent, being almost complete at ALG concentrations of 100 ,ug/ml. Inhibition was a property of ALG but not of normal horse globulin. However, short incubation of ALG with bone marrow cells occasionally stimulated colony growth and normal horse globulin regularly stimulated it. Three hours' incubation of bone marrow cells with ALG was needed to produce consistent colony inhibition, which was measurable as a reduction in the expected number of colonies and as a fall in the colony: cluster ratio of surviving cell aggregates. Absorption of ALG on acute myeloid leukaemia blast cells removed the inhibiting property of the ALG while preserving its lymphocytotoxic action. Serum from two patients receiving ALG treatment inhibited colony growth for up to 48 hours after ALG administration. The results suggest the presence in ALG of antibodies specifically cytotoxic to myeloid stem cells which may relate to its myelosuppressive properties in vivo, and also indicate that it should be possible to remove antimyeloid antibodies from ALG by absorption. The use of such purified ALG would have advantages in clinical bone marrow transplantation.
Antilymphocyte globulin (ALG) and antithymocyte globulin (ATG) inhibit human granulocyte colony growth (Rodt et al., 1974; Barrett et al., 1975) . There is evidence from animal experiments that ALG also inactivates bone marrow stem cells in vivo and in vitro (Field and Gibbs, 1968; DeMeester et al., 1968) , and ALG and ATG have occasionally been implicated in the failure of bone marrow transplants to establish a graft in patients with aplastic anaemia (Storb et al., 1974; Barrett et al., 1975) . We have investigated (1) the inhibition of human granulocyte colony-forming cells (CFU) by ALG, (2) methods to remove this inhibition, and (3) the cliuical relevance of this interaction.
Material and methods
The ALG preparations tested are shown in Received for publication 28 July 1977 counted and the volume of the cell suspension was adjusted to obtain 106 cells/ml: 0 7 ml volumes of this suspension were pipetted into sterile tubes containing either 01 ml normal horse globulin (NHG) or ALG in final concentrations varying from 100 to 0-1 ,ug/ml: 0-2 ml of fresh autologous serum was added to each tube. In some experiments duplicate tubes were prepared with autologous serum heated to 560C for 30 minutes to inactivate complement. A control tube containing 0-2 ml serum but no horse globulin was also prepared for each experiment. The cells were incubated at 370C for varying periods of time in different experiments. They were then washed twice in McCoy 5A medium containing 15% fetal calf serum or human AB serum and put into culture.
GRANULOCYTE COLONY CULTURE
Colony culture followed the technique described by Pike and Robinson (1970) , but in later experiments 15 % human AB serum was used in place of fetal calf serum since it was found to support colony growth better. The washed cell buttons obtained by centrifugation after incubation with globulin were resuspended in 3-5 ml of 0-3 % agar and medium and 1-ml volumes were pipetted into triplicate culture dishes on blood leucocyte feeder layers in 05 5% agar prepared at least four days in advance to avoid interference of any residual ALG with colony-stimulating factor production by the feeder layer.
Colonies were counted after 12 to 14 days' incuba- Acute myeloid leukaemia (AML) blast cells were obtained by kind permission of Dr R. Powles from an untreated patient undergoing leucopheresis. This preparation was preserved at -700C in dimethyl sulphoxide. It contained over 99% myeloblasts and no lymphocytes.
ALG 2 was absorbed overnight on washed preparations of packed cells in the ratio of 1 mg of globulin to 108 cells. The mixture was resuspended and incubated for a further hour before centrifugation at 600 g. The clear supernatant was then removed for testing. Using packed leucocytes the volume of globulin before and after absorption did not alter significantly, and absorbed globulin was diluted identically with the unabsorbed globulin for testing at concentrations of 100, 10, and 1 0 ,ug/ml.
LYMPHOCYTOTOXICITY TESTS
ALG was tested for lymphocytotoxicity by the Terasaki two-step method in microtoxicity plates. Of each globulin dilution 1 ,ul was added to 2 ,l of lymphocytes obtained from normal individuals and incubated for I hour before adding rabbit complement. The cells were incubated for a further Ij hours. Eosin was then added and cytotoxicity assessed using an inverted objective microscope. The globulin was tested absorbed and unabsorbed at final concentrations of 100, 10, and 1 ug/ml on lymphocytes from normal subjects. Results were expressed as the mean lymphocytotoxicity for four experiments using a different lymphocyte donor on each occasion.
TESTS USING SERUM OF PATIENTS TREATED WITH ALG
Two patients were given 40 mg/kg/day of ALG 2 for five days by intravenous infusion during treatment for pure red cell aplasia (case A) and severe aplastic anaemia (case B). Blood was taken before, during, and after ALG administration; serum was separated and stored at -40°C and tested for colony-inhibiting properties on a single bone marrow sample. 106 nucleated cells in 0-7 ml were incubated for two hours at 37°C with 0-2 ml volumes of patients' serum and 01 ml of fresh AB serum and the cells were then washed and put into culture.
Results

EFFECT OF COMPLEMENT AND COMPARISON OF ALG WITH NORMAL HORSE GLOBULIN
A preliminary experiment showed that ALG 1 inhibited colony growth in a dose-dependent manner and that the effect was enhanced by fresh autologous serum used as a source of complement (Fig. 1) .
The results of three similar experiments are shown in Table 2 . Inhibition was greater in the presence of a source of complement, but this difference was reproducibly significant only for concentrations of globulin of 100 ,ug/ml. ALG in the absence of complement showed significant inhibition only when compared with NHG at concentrations down to 10 ,ug/ml, while the addition of complement produced significant inhibition at concentrations as low as 1 ,ug/ml. The mean results of these two experiments are shown in Figure 3 . All preparations showed inhibition; only one (ALG 7) was significantly less inhibitory and NHG did not cause dose-dependent inhibition. Analysis of the colony:cluster ratio in these experiments showed a close correlation between the degree of inhibition observed and the fall in the colony: cluster ratio (r = 096; P = 0001, Fig. 4 ).
COLONY INHIBITION IN SERUM OF PATIENTS TREATED WITH ALG
Serum from two patients during ALG administration inhibited colony growth after 48 hours (case B) and after 24 hours (case A). Serum taken before ALG administration did not inhibit colony growth when compared with a control (autologous) serum (Table  4) . ALG absorbed to remove stem cell toxicity would have advantages in three situations: (1) in the experimental treatment of aplastic anaemia with ALG alone, (2) in bone marrow transplantation to permit early postgraft treatment (or prophylaxis) of graft versus host disease, and (3) in the preincubation of the bone marrow graft with ALG to eliminate mature lymphocytes from the graft. This last procedure has successfully prevented graft versus host disease in incompatible donor-recipient matches in mice (Trentin and Judd, 1973) and rats (MullerRucholz et al., 1976) and might find clinical application in situations where no fully compatible donor was available for a patient with severe aplastic anaemia. These experiments show that it is possible selectively to remove anti-CFU activity in ALG by absorption, and other studies using fetal liver cells as an absorbing antigen have produced similar results (Mosedale et al., 1976) . However, there would be practical difficulties in obtaining sufficient fetal liver cells for preparing therapeutic amounts of ALG.
The possibility also remains that the removal of CFU inhibition does not correlate with any reduction in toxicity to the totipotential stem cell responsible for marrow engraftment. Antigens present on spleen CFU and not on agar CFU have been identified in the mouse (Golub, 1972) , and until a human stem cell assay is available the efficacy of absorption in removing anti-stem cell activity could be confirmed only by clinical trial.
